A Neoadjuvant Study of Sintilimab Plus Platinum Doublet Chemotherapy in IIIA(N2) Stage NSCLC
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the feasibility and evaluate the safety of
delivering chemotherapy, the usual approach to non-small cell lung cancer, in combination
with Sintilimab (PD-1 antibody), followed by adjuvant therapy after surgical resection.
Consolidation therapy is treatment given following the initial treatment.
Sintilimab is an investigational drug, which has been approved by the NMPA(National Medical
Products Administration,China. https://www.nmpa.gov.cn/) for use in late stage of non-small
cell lung cancer (NSCLC). Sintilimab is a monoclonal antibody that binds to the surface of
some cells of the immune system and activates them against cancer cells. It is not
chemotherapy.